{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"negative_space_design__pharmacology_toxicology","archetype_slug":"negative_space_design","domain_slug":"pharmacology_toxicology","title":"Measurement-gated recovery between sequential toxicology exposures","opportunity_summary":"In reusable organoid or microphysiological toxicology models, delay each subsequent compound exposure until residual analyte, viability, and selected baseline biomarkers satisfy prespecified recovery gates, with the aim of reducing carryover and improving attribution relative to a fixed washout. The candidate is a testable hypothesis; the frequency of consequential baseline carryover and the benefit of the proposed gates remain unestablished.","adopter_authorizer":"The study principal investigator and assay owner, subject to institutional biosafety, ethics, and quality-system requirements.","scores":{"meaningful_impact":{"score":4,"rationale":"If sequential carryover materially biases hazard estimates, reducing it could improve attribution and reproducibility for consequential safety decisions. Impact is limited to reusable sequential-exposure systems, and the sealed candidate provides no evidence of problem prevalence."},"stakeholder_pull":{"score":3,"rationale":"Toxicology investigators, assay owners, and downstream safety assessors have a plausible interest in fewer order effects and inconclusive experiments, but no expressed demand, adoption inquiry, or evidence that carryover is a recurring operational priority is supplied."},"incremental_advantage":{"score":3,"rationale":"State-dependent release could detect residual analytes or persistent biomarker deviation missed by a fixed-duration washout. Its net advantage is uncertain because measured recovery may not represent latent adaptation, and variable delays can reduce viability or throughput."},"distinctiveness_plausibility":{"score":3,"rationale":"Measurement-gated recovery is operationally distinguishable from the stated fixed-washout baseline and has a separate falsifiable claim, but prior art is explicitly unsearched, so external distinctiveness cannot be credited."},"technical_implementability":{"score":4,"rationale":"The intervention uses bounded withholding, continued biological support, residual-analyte assays, viability measures, biomarkers, and protocol records already specified by the candidate. Implementability is constrained by marker validity, gate calibration, culture-duration limits, and model instability."},"adoption_authority_feasibility":{"score":4,"rationale":"The candidate identifies the principal investigator and assay owner as decision-makers and confines the first step to an in-laboratory pilot with existing governance. Quality-system approval and assay-specific validation may still be required."},"evidence_readiness":{"score":3,"rationale":"A preregistered comparison, observable outcomes, problem and intervention falsifiers, stop thresholds, and rollback are specified. No empirical results, validated recovery thresholds, sample plan, or evidence that selected biomarkers capture relevant latent carryover is provided."},"safety_net_benefit":{"score":4,"rationale":"The method could serve as a check against attributing residual or order-dependent effects to the current compound, while explicit viability stops, duration caps, record retention, and rollback limit pilot risk. It cannot establish restoration of the original biological state or clinical safety."},"scalability":{"score":3,"rationale":"The gating pattern could be repeated across reusable platforms, but analytes, metabolites, biomarkers, recovery kinetics, and validated culture limits may differ by compound and model, creating substantial assay-specific validation and throughput burdens."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"One preregistered two-compound pilot in independent reusable model units comparing the existing fixed washout with measurement-gated recovery, including analytical measurements, viability and biomarker assays, protocol preparation, data analysis, quality review, and the added culture cycle.","confidence":"LOW","assumptions":["A suitable reusable model and baseline protocol already exist.","The laboratory has access to the necessary culture and analytical capabilities.","The pilot remains within one additional planned culture cycle and does not require development of a new measurement platform.","The sealed candidate does not specify replicate counts, compound complexity, or data-access terms."]},"initial_deployment_startup":{"band_2026_usd":"50K_TO_250K","scope":"Assay-specific gate validation for one laboratory and one reusable model workflow, including threshold selection, SOP and record-system changes, operator training, quality review, and initial validation runs.","confidence":"LOW","assumptions":["Deployment follows favorable pilot results.","Existing equipment and core laboratory infrastructure are reused.","The initial scope covers one platform and a limited compound workflow.","No regulated submission or major automation build is included."]},"operational_launch":{"band_2026_usd":"50K_TO_250K","scope":"Controlled launch within one laboratory program, including qualification runs, routine measurement setup, scheduling changes, quality oversight, operator support, and evaluation of viability and throughput effects.","confidence":"LOW","assumptions":["Recovery gates and stop thresholds have already been validated for the launch scope.","Launch does not extend beyond validated culture duration.","Analytical testing can be handled by existing internal or contracted capacity.","The number and diversity of compounds remain limited."]},"annual_recurring":{"band_2026_usd":"50K_TO_250K","scope":"Incremental annual resources for residual-analyte and biomarker measurements, additional culture maintenance, operator and quality labor, data review, failed or capped recovery intervals, and throughput displacement in a single laboratory program.","confidence":"LOW","assumptions":["Use is limited to sequential experiments on one established reusable platform.","Testing frequency and compound volume are moderate but unspecified.","No major equipment replacement is required.","Variable recovery intervals create some recurring throughput loss."]}},"research_burden":"HIGH","earliest_credible_horizon":"3_TO_12_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"YES","reason":"The proposed problem is recognizable through residual analyte, pre-exposure biomarker deviation, exposure-order effects, and response variability. Whether it occurs materially under the baseline protocol remains to be tested."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"The sealed candidate identifies toxicology investigators and assay operators as adopters and the study principal investigator and assay owner as decision authorities, subject to institutional requirements."},"distinct_testable_incremental_claim":{"status":"YES","reason":"The candidate claims that measurement-gated recovery will reduce residual state, order effects, or response variance relative to fixed washout without unacceptable viability or throughput loss; this is distinct and falsifiable."},"bounded_next_evidence_step":{"status":"YES","reason":"The specified two-compound, independent-unit pilot compares fixed washout with gated recovery, caps delay at one additional culture cycle, measures defined outcomes, and includes explicit failure and halt criteria."},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"The pilot excludes human and animal dosing, preserves essential support, stays within validated culture duration, names responsible authority, and provides viability, contamination, delivery-failure, duration-cap, record-retention, and rollback controls."},"implementation_cost_scope_and_range":{"status":"UNCERTAIN","reason":"The candidate identifies the main operational components, permitting broad conditional bands, but omits replicate counts, measurement platforms, compound complexity, laboratory capacity, workflow volume, and validation obligations needed to establish a reliable implementation range."}},"blocking_evidence":["No sealed evidence shows that residual analytes, baseline deviations, or material order effects persist after the existing fixed washout.","The validity of the selected recovery biomarkers as proxies for latent carryover or adaptation is unknown.","No comparative evidence shows that gating improves attribution or variance without unacceptable viability loss, model aging, selective exclusion, or throughput reduction.","Prior art and current practice are unsearched, so distinctiveness and the extent to which comparable controls already exist are unknown.","Resource requirements depend on unspecified replicate counts, analytical methods, compound diversity, platform capacity, and quality obligations."],"next_evidence_step":"Run the authorized preregistered two-compound pilot in independent reusable model units, comparing the existing fixed washout with recovery-gated intervals capped at one additional planned culture cycle. Measure residual analyte, viability, baseline biomarkers, order effects, response variance, and throughput. Do not advance if the baseline problem falsifier is met, or if gating fails to reduce residual state, order effects, or variance relative to fixed washout without unacceptable viability or throughput costs.","research_questions":["Under the validated fixed-washout protocol, how often do residual analytes, baseline deviations, or material order effects remain across the tested exposure orders?","Do the selected analyte and biomarker gates predict subsequent carryover better than elapsed washout time alone?","Does gated recovery reduce order effects or response variance relative to fixed washout while preserving viability, function, and acceptable throughput?","Does the added interval introduce model aging, delayed toxicity, remodeling, adaptation, or selective exclusion of slow-recovering conditions?","How compound-specific and model-specific must the gate panel and thresholds be?","Do existing protocols or prior art already use equivalent state-dependent release criteria?","What laboratory volume, measurement platform, validation scope, and quality requirements determine implementation cost?"] ,"recommendation":"VALIDATE_PROBLEM_FIRST","uncertainty_constraints":["Problem prevalence and severity are unmeasured outside the proposed pilot context.","World novelty and prior art are unmeasured.","Market size and stakeholder demand are unmeasured.","Recovery-marker coverage of latent biological state is unknown.","Generalizability across compounds, metabolites, organoids, and microphysiological systems is unknown.","All cost bands are conditional resource-equivalent estimates because operational quantities are absent."],"closed_book_prior_art_boundary":"The candidate labels prior art as UNSEARCHED, and this assessment used no external sources. No claim is made about novelty, prevalence, market size, existing commercial or academic implementations, realized impact, or exact cost."}